Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of EMB-01 in advanced or metastatic gastrointestinal cancers
CTR20220158Phase 2Active
- Sponsor
- EpimAb Biotherapeutics
- Start
- Apr 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of emb-01 in gastric cancer (GC), hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), colorectal cancer (CRC), gastrointestinal cancer, sponsored by EpimAb Biotherapeutics. Started Apr 2022; status: active.
02
Drugs
emb-01
03
Conditions
gastric cancer (GC)hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)colorectal cancer (CRC)gastrointestinal cancer
Beyond the preview
Go deeper on CTR20220158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220158.